Total raised
$31.0M
Last: Series A 2025-06
Stage
Series A
Founded
2018
Headcount
9
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
Kamari Pharma is a biopharmaceutical company aiming to develop and commercialize proprietary small molecule inhibitors of TRPV3, a cation channel expressed primary in keratinocytes, for the treatment of dermatological conditions with unmet need. TRPV3 has been extensively evaluated as a target for drug development, identified as the cause of Olmsted syndrome in humans, and shows involvement in various skin disorders including keratoderma, atopic dermatitis, psoriasis, rosacea, and post-burn pruritus.
Funding history · 3 rounds · $31.0M total
2025-06
Series A
$23.0M
2022-09
Undisclosed
$8.0M
2020-01
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was Kamari Pharma founded?
- Kamari Pharma was founded in October 2018.
- What is Kamari Pharma's primary focus?
- Kamari Pharma is a biopharmaceutical company focused on developing and commercializing proprietary small molecule inhibitors of TRPV3 for dermatological conditions.
- How much total funding has Kamari Pharma raised to date?
- Kamari Pharma has raised a total of $31,000,000 in funding.
- When did Kamari Pharma close its Series A financing round?
- Kamari Pharma announced the closing of its $23 million Series A financing round in June 2025. The round was led by Pontifax and BRM Group.
- Which investors participated in Kamari Pharma's undisclosed round in January 2020?
- In January 2020, Kamari Pharma received investment from Arkin Bio and Pontifax in an undisclosed round.
- What was the amount and lead investor for Kamari Pharma's funding round in September 2022?
- In September 2022, Kamari Pharma raised $8,000,000 from Guangzhou Sino-Israel Biotech Investment Fund (GIBF).
- What is the current employee count for Kamari Pharma?
- Kamari Pharma currently has 9 employees.
- What significant operational development did Kamari Pharma undergo in April 2026?
- In April 2026, Kamari Pharma changed its name and began clinical trials for a drug targeting a skin disease.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
biopharmaceuticaldrug-developmentdermatologypharma-companiesskinrare-diseasespharmaceuticals